Abstract

Objective To explore the mechanism of action of Bu-Fei-Yi-Shen formula (BFYSF) in treating chronic obstructive pulmonary disease (COPD) based on network pharmacology analysis and molecular docking validation. Methods First of all, the pharmacologically active ingredients and corresponding targets in BFYSF were mined by the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, the analysis platform, and literature review. Subsequently, the COPD-related targets (including the pathogenic targets and known therapeutic targets) were identified through the TTD, CTD, DisGeNet, and GeneCards databases. Thereafter, Cytoscape was employed to construct the candidate component-target network of BFYSF in the treatment of COPD. Moreover, the cytoHubba plug-in was utilized to calculate the topological parameters of nodes in the network; then, the core components and core targets of BFYSF in the treatment of COPD were extracted according to the degree value (greater than or equal to the median degree values for all nodes in the network) to construct the core network. Further, the Autodock vina software was adopted for molecular docking study on the core active ingredients and core targets, so as to verify the above-mentioned network pharmacology analysis results. Finally, the Omicshare database was applied in enrichment analysis of the biological functions of core targets and the involved signaling pathways. Results In the core component-target network of BFYSF in treating COPD, there were 30 active ingredients and 37 core targets. Enrichment analysis suggested that these 37 core targets were mainly involved in the regulation of biological functions, such as response to biological and chemical stimuli, multiple cellular life processes, immunity, and metabolism. Besides, multiple pathways, including IL-17, Toll-like receptor (TLR), TNF, and HIF-1, played certain roles in the effect of BFYSF on treating COPD. Conclusion BFYSF can treat COPD through the multicomponent, multitarget, and multipathway synergistic network, which provides basic data for intensively exploring the mechanism of action of BFYSF in treating COPD.

Highlights

  • Chronic obstructive pulmonary disease (COPD) is a common clinical disease characterized by respiratory system symptoms and flow limitation [1]

  • It is generally induced by airway and alveolar abnormalities due to exposure to harmful particles and gases, and its pathogenesis is mainly related to chronic airway and pulmonary inflammation, oxidative stress (OS), protease/antiprotease imbalance, and cell apoptosis [2,3,4,5]

  • Using the Traditional Chinese Medicine Systems Pharmacology (TCMSP, Version: 2.3, https://tcmspw.com/index.php) database and the analysis platform [21], the names of six Chinese herbal medicines were input in succession to obtain the corresponding chemical compounds and related information

Read more

Summary

Introduction

Chronic obstructive pulmonary disease (COPD) is a common clinical disease characterized by respiratory system symptoms and flow limitation [1]. It is generally induced by airway and (or) alveolar abnormalities due to exposure to harmful particles and gases (like cigarette smoke), and its pathogenesis is mainly related to chronic airway and pulmonary inflammation, oxidative stress (OS), protease/antiprotease imbalance, and cell apoptosis [2,3,4,5]. In China, COPD is a major chronic respiratory system disease that severely impairs human health [7, 8]. Traditional Chinese medicine (TCM) exhibits obvious advantages in the treatment of COPD, which obviously improves

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call